<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01367301</url>
  </required_header>
  <id_info>
    <org_study_id>11-02-064</org_study_id>
    <secondary_id>NCI-2013-01225</secondary_id>
    <secondary_id>10-089</secondary_id>
    <secondary_id>11-02-064</secondary_id>
    <secondary_id>P30CA013330</secondary_id>
    <nct_id>NCT01367301</nct_id>
  </id_info>
  <brief_title>Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer</brief_title>
  <official_title>A Pilot Trial of Radiation Therapy &quot;Sandwiched&quot; Between Paclitaxel and Carboplatin in Patients With Uterine Carcinosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies radiation therapy, paclitaxel, and carboplatin in treating&#xD;
      patients with uterine cancer. Radiation therapy uses high-energy x-rays to kill tumor cells.&#xD;
      Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to&#xD;
      stop the growth of tumor cells, either by killing the cells or stopping them from dividing.&#xD;
      Giving radiation with chemotherapy may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the one year recurrence-free survival in patients with uterine carcinosarcoma&#xD;
      treated with &quot;sandwich&quot; therapy-including defining the patterns of recurrence in patients&#xD;
      with carcinosarcoma who were treated with this regimen.&#xD;
&#xD;
      II. To evaluate the toxicity and tolerability of pelvic radiation &quot;sandwiched&quot; between cycles&#xD;
      of paclitaxel/carboplatin chemotherapy in patients with uterine carcinosarcoma.&#xD;
&#xD;
      III. To correlate surrogate endpoint biomarkers with progression-free survival and prognosis.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      CHEMOTHERAPY (weeks 1-9, 14-22): Patients receive paclitaxel intravenously (IV) over 3 hours&#xD;
      and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses&#xD;
      during weeks 1-9 and 14-22.&#xD;
&#xD;
      RADIATION THERAPY (weeks 8-16): Patients undergo external beam pelvic radiation therapy once&#xD;
      a day, 5 days a week for 5 weeks during weeks 8-13. Patients then undergo high dose radiation&#xD;
      (HDR) brachytherapy or intensity-modulated radiation therapy (IMRT) once weekly during weeks&#xD;
      14-16.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 2 years,&#xD;
      every 6 months for 3 years, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    There was a lack of accrual&#xD;
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2019</completion_date>
  <primary_completion_date type="Actual">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>Date of entry to date of reappearance of disease, assessed at 1 year</time_frame>
    <description>One-year recurrence-free survival probability will be estimated, with 95% confidence limits based on exact methods for the binomial distribution.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Stage IA Uterine Sarcoma</condition>
  <condition>Stage IB Uterine Sarcoma</condition>
  <condition>Stage IC Uterine Sarcoma</condition>
  <condition>Stage IIA Uterine Sarcoma</condition>
  <condition>Stage IIB Uterine Sarcoma</condition>
  <condition>Stage IIIA Uterine Sarcoma</condition>
  <condition>Stage IIIB Uterine Sarcoma</condition>
  <condition>Stage IIIC Uterine Sarcoma</condition>
  <condition>Stage IVA Uterine Sarcoma</condition>
  <condition>Stage IVB Uterine Sarcoma</condition>
  <condition>Uterine Carcinosarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (paclitaxel, carboplatin, radiotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHEMOTHERAPY (weeks 1-9, 14-22): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 14-22.&#xD;
RADIATION THERAPY (weeks 8-16): Patients undergo external beam pelvic radiation therapy once a day, 5 days a week for 5 weeks during weeks 8-13. Patients then undergo HDR brachytherapy or IMRT once weekly during weeks 14-16.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, radiotherapy)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, radiotherapy)</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>external beam radiation therapy</intervention_name>
    <description>Undergo external beam radiation therapy</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, radiotherapy)</arm_group_label>
    <other_name>EBRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
    <description>Undergo HDR brachytherapy</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, radiotherapy)</arm_group_label>
    <other_name>low-LET implant therapy</other_name>
    <other_name>radiation brachytherapy</other_name>
    <other_name>therapy, low-LET implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, radiotherapy)</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, radiotherapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically documented uterine carcinosarcoma with no visible residual disease&#xD;
&#xD;
          -  Surgical staging to include total abdominal hysterectomy, bilateral&#xD;
             salpingo-oophorectomy, peritoneal washings, and lymph node samplings&#xD;
&#xD;
          -  Patients must be entered no more than 12 weeks post operatively&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of &lt; 2&#xD;
&#xD;
          -  Written voluntary informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) and /or serum glutamate pyruvate&#xD;
             transaminase (SGPT) &gt; 2.5 times the institutional upper limit of normal&#xD;
&#xD;
          -  Total serum bilirubin &gt; 1.5 mg/dl&#xD;
&#xD;
          -  History of chronic or active hepatitis&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0 mg/dl&#xD;
&#xD;
          -  Platelets &lt; 100,000/mm3&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt; 1500/mm3&#xD;
&#xD;
          -  Hemoglobin &lt; 8.0 g/dl (the patient may be transfused prior to study entry)&#xD;
&#xD;
          -  Patient has severe or uncontrolled concurrent medical disease (e.g. uncontrolled&#xD;
             diabetes, unstable angina, myocardial infarction within 6 months, congestive heart&#xD;
             failure, etc.)&#xD;
&#xD;
          -  Patient with any prior chemotherapy or radiotherapy for pelvic malignancy&#xD;
&#xD;
          -  Patients with any history of cancer with the exception of non-melanoma skin cancer are&#xD;
             excluded if there is any evidence of other malignancy being present within the past&#xD;
             five years&#xD;
&#xD;
          -  Patients with dementia or altered mental status that would prohibit the giving and&#xD;
             understanding of informed consent at the time of study entry&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merieme Klobocista</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis Yi-Shin Kuo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 3, 2011</study_first_submitted>
  <study_first_submitted_qc>June 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2011</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Carcinosarcoma</mesh_term>
    <mesh_term>Mixed Tumor, Mullerian</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

